PD-0498: Use of STAT in prostate cancer: correlation with risk factors and identification of residual cohort  by Rancati, T. et al.
S194  2nd ESTRO Forum 2013	
 
  
Conclusions: The access to federated multi-centric data enables 
creating more reliable and more robust models than those based on 
single-center data. The infrastructure has inherent external validation 
capabilities that are available at virtually no extra cost of time. There 
is therefore an enormous potential of using such kind of infrastructure 
for learning more accurate and reliable medical prediction models in 
the future.  
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Purpose/Objective: To determine a self consistent set of 
radiobiological parameters in prostate cancer. 
Materials and Methods: A method to estimate intrinsic 
radiosensitivity (α), fractionation sensitivity (α/β), repopulation 
doubling time (Td), number of clonogens (N) and kick-off time for 
accelerated repopulation (Tk) of prostate cancer, has been developed. 
Based on the generalized linear quadratic model (LQ) and without 
assuming the iso-effective hypothesis, the potential applications of 
the method were investigated using the clinical outcome of the 
biochemical relapse free survival (bRFS) recently reviewed in 
literature. The strength and limitation of the method, regarding the 
fitted parameters and 95% confidence intervals, are also discussed. 
Results: Our best estimate of α/β is 2.96 Gy (2.41-3.53)95%. The 
correspondent α valueis 0.16 Gy-1 (0.14-0.18)95% which is compatible 
with a realistic number of clonogens: 6.5·106 (1.5·106-2.1·107)95%. The 
estimated cell doubling time Td is 5.1 days (4.2-7.2)95%, very low if 
compared to that reported in literature. This corresponds to the dose 
required to offset the repopulation occurring in one day (Dprolif) of 
0.51 Gy/day (0.32-0.68)95%. However, a long kick-off time Tk of 31 
days (22-41)95% from the start of radiotherapy was found. 
Conclusions: The proposed analytical/graphical method has allowed 
to fit clinical data providing a self-consistent set of radiobiological 
parameters for prostate cancer. With our analysis we confirm a low 
value for α/β with a correspondingly high value of intrinsic 
radiosensitivity, a realistic average number of clonogens, a long kick-
off time for accelerated repopulation and a surprisingly fast 
repopulation that suggests the involvement of subpopulations of 
specifically tumorigenic stem cells during the continuing radiotherapy. 
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Purpose/Objective: Standardized Total Average Toxicity (STAT) score 
was proposed by Barnett (IJROBP11) as a global score which may be 
used to:  
(a) facilitate the analysis of overall radiation (RT) toxicity (tox) 
(b) pool data from multiple trials (in order to increase statistical 
power) 
(c) select patients (pts) to be included in studies of possible genetic 
determinants of RT tox. 
In the same paper application of STAT to 2 cohorts of breast cancer 
pts was presented. 
We here evaluate application of STAT to 2 prostate cancer populations 
(A and B), with the aim of verifying that STAT keeps all known 
correlations of single tox endpoints with clinical/dosimetric risk 
factors and to select possible radiosensitive pts 
Materials and Methods: Population A (646 pts, doses 70-80Gy,1.8-
2Gy/fr) was included in a prospective trial on rectal tox (recorded by 
questionnaires). 
Population B (179 pts, doses 60-80Gy,1.8-2.65Gy/fr) was included in a 
prospective trial on genito-urinary tox (measured by IPSS). STAT 
calculation was made following definition by Barnett. Key point is that 
STAT defines whether a pt’s global tox is high or low relative to the 
distribution of the global tox of other pts. STAT measures the distance 
between the single pt and the average of all considered pts in terms 
of standard deviations.  
For population A, 2 STATs were considered: baseline STAT (BSTAT) 
and late (3yrs follow-up) STAT (STATGI). For population B, only acute 
tox was available and acute STAT (STATGU) was calculated. We 
considered pts with STATGI/STATGU>0.8 as exhibiting high tox with 
respect to the whole cohort and clinical/dosimetric predictors of 
STATGI/STATGU>0.8 were determined through multivariable logistic 
analysis. Analysis of residuals was used to individuate the 
radiosensitive cohorts 
Results: STATGI>0.8 (43/646pts) was predicted by: BSTAT (continuous 
variable (cv), OR=2, p=0.04), previous diseases of the colon (OR=3, 
p=0.02), the % volume of rectum receiving more than 40Gy (V40Gy, 
cv, OR=1.02, p=0.08) and V75Gy (cv, OR=1.05, p=0.03). Overall 
p=0.0006, AUC 0.74. 
STATGU>0.8 (39/179pts) was predictedby: pre-RT IPSS (cv, OR=1.14, 
p=0.0008), Body Max Index (cv, OR=0.94, p=0.2), clinical T3 stage 
(OR=2, p=0.1), absolute bladder surface receiving ≥8.5 Gy/week (cv, 
OR=1.014, p=0.03) and absolute bladder surface receiving ≥12.5 
Gy/week (cv, OR=1.035, p=0.06). Overall p<0.0001, AUC 0.81. 
From analysis of residuals, 14 and 11 pts emerged as possible 
radiosensitive pts (with high STAT which is not predicted from model) 
for STATGI and STATGU, respectively. 
 
 
Conclusions: Correlation between high STATGI/STATGU and 
clinical/dosimetric risk factors confirmed previously results found in 
the 2 populations for the single tox endpoints. 
This global approach allows objective identification of pts whose tox 
are not explained by the global model and who may be included in 
studies of possible genetic determinants of RT tox 
 
 
 
 
